Amorfix diagnostics have a primary focus of detecting disease early. Early detection of Alzheimer's Disease or liver cancer will lead to earlier treatment of the disease and the potential for better patient outcomes. Earlier detection will also lead to the development of more effective treatments that can be tested at much earlier stages of the disease by clearly identifying the treatment population for clinical studies.
Earlier detection of disease requires technologies that provide for the detection of very small amounts of disease-causing proteins. In misfolded protein diseases like Alzheimer's, normal proteins have been induced to misfold and aggregate. Since there is an abundance of normal protein in blood, these protein aggregates are extremely difficult to find. It is like looking for stars on a sunny day; the stars are shining but they cannot be seen in the sunlight. Amorfix's Epitope Protection technology is a chemical process to hide all the normal proteins and make the aggregated proteins stand out; a way to block out the sun so the stars can be seen. Amorfix has also developed an ultrasensitive immunoassay platform to detect small amounts of protein (that can be used alone or in combination with Epitope Protection); using our analogy, this is like using a Hubble telescope to see even the faintest stars.
- It is hard to see aggregated misfolded proteins among the normal proteins
- With Epitope Protection the normal proteins become visible
Misfolded proteins can also be detected if you can predict what they look like when they misfold and change shape. Amorfix's ProMISTM targeting identification technology can predict the shape of the misfolded protein and predict regions of the protein - Disease Specific Epitopes (DSEs) - that were not accessible in its normal conformation. By identifying these previously unaccessible regions and targeting them with antibodies as detection devices, disease-specific assessments can be made when these misfolded proteins are found. Measuring the quantity of these AMPs in blood over time during treatment may also provide a useful tool to assess the impact of treatment on the patient.
Antibodies raised to DSEs on misfolded proteins could also be used to treat disease as Amorfix has demonstrated in preclinical studies in its ALS program.
Diagram: Amorifix Diagnostic Strategy
Amorfix's diagnostics rely on a variety of proprietary technologies which allow for the isolation and detection of aggregated or misfolded proteins
- Patient blood or biofluid sample
- Masking of normal protein
- Detection of aggregate using a sensitive and rapid assay
A4 - Amorfix Aggregated Aβ Assay
The A4 test is a highly sensitive and quantitative immunoassay that detects aggregated Aβ in cell culture, plasma and brains of Alzheimer's Disease mouse models.
Custom Assay Development Services
We apply our expertise in assay development to design sensitive immunoassays for other proteins. The Dual Bead Platform can be used for detecting proteins that are in very low concentration in a sample.